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InterferonThe infection of cells by RNA viruses is associated with the recognition of virus PAMPs (pathogen-associated
molecular patterns) and the production of type I interferon (IFN). To counter this, most, if not all, RNA
viruses encode antagonists of the IFN system. Here we present data on the dynamics of IFN production and
response during developing infections by paramyxoviruses, inﬂuenza A virus and bunyamwera virus. We
show that only a limited number of infected cells are responsible for the production of IFN, and that this
heterocellular production is a feature of the infecting virus as opposed to an intrinsic property of the cells. license. © 2010 Elsevier Inc. Open access under CC BY license. Introduction
Virus infection leads to rapid activation of the innate immune
response of the host that is associated with a short-term restriction
of virus replication. One of the main components of the innate anti-
viral response is type I interferon (IFN), a group of closely-related
cytokines. Type I IFNs signal through a common receptor to up-
regulate over 400 genes (the so-called IFN-stimulated genes, or ISGs)
by activating the well-characterised JAK/STAT pathway (Platanias,
2005; Randall and Goodbourn, 2008). Many of the ISGs, including
protein kinase R (PKR), 2′5′ oligoadenylate synthetase (OAS) and
MxA have anti-viral activity, and thereby act to limit the spread of the
virus (Sen and Peters, 2007).
IFN induction requires the recognition of pathogen-associated
molecular patterns (PAMPs), which are seen as foreign by pattern
recognition receptors (PRRs, reviewed in Takeuchi and Akira, 2009).
Twowell-characterised cytoplasmic PRRs, retinoic acid inducible gene
I (RIG-I), and melanoma differentiation-associated gene-5 (mda-5)
are thought to recognise respectively blunt short double-stranded 5′-
triphosphorylated RNA or long dsRNA (Kato et al., 2008; Schlee et al.,
2009; Schmidt et al., 2009), and are thus of considerable importance
in mediating IFN induction by RNA viruses (reviewed in Wilkins and
Gale).
To survive in nature all viruses appear to require a strategy to
circumvent the IFN response. The evasion strategies can be classiﬁed
as (i) generally inhibiting cellular transcription and/or protein
synthesis, (ii) speciﬁcally inhibiting components of the IFN-induction
or IFN-signalling pathways, or (iii) inhibiting IFN-induced factors that
have anti-viral activity (Randall and Goodbourn, 2008). The nature ofIFN antagonists encoded by small negative-sense RNA viruses reﬂects
these processes. As examples, the NSs protein of bunyamwera virus
(BUNV) inhibits cellular transcription, thereby inhibiting both the
production of IFN and the ability of infected cells to respond to IFN
(Thomas et al., 2004); the NS1 protein of inﬂuenza A viruses (FLUAV)
is a multifunctional protein that speciﬁcally inhibits RIG-I activation,
generally interferes with cellular protein expression by inhibiting the
correct processing and export of cellular mRNAs from the nucleus to
cytoplasm, and blocks the activity of PKR and OAS (Hale et al., 2008).
The IFN antagonists of paramyxoviruses speciﬁcally block both IFN
induction and IFN signalling, although the exact molecular mechan-
isms by which they achieve this vary between different viruses
(Fontana et al., 2008; Goodbourn and Randall, 2009; Ramachandran
and Horvath, 2009); thus, the V protein of parainﬂuenza virus type 5
(PIV5) blocks IFN signalling by catalytically targeting STAT1 for
proteasome-mediated degradation (Didcock et al., 1999; Precious
et al., 2005, 2007), whereas the V protein of parainﬂuenza virus type 2
(PIV2) targets STAT2 for degradation (Parisien et al., 2001). The V
proteins of paramyxoviruses block IFN induction (Poole et al., 2002;
He et al., 2002) by binding to mda-5 (Andrejeva et al., 2004; Childs
et al., 2007) and preventing its dimerisation (Childs et al., 2009),
whilst the C protein of Sendai virus (SeV) blocks IFN induction
through RIG-I (Strahle et al., 2007).
Despite the existence of potent virus-encoded antagonists of the
IFN system, IFN can still exert an anti-viral effect that limits the
production of virus. This is supported by the observation that RNA
viruses produce larger plaques on cells that have been engineered to
either fail to produce or respond to IFN than they do on unmodiﬁed
‘IFN-competent’ cells (Young et al., 2003). The apparent incomplete
block to the IFN system suggests that the spread of a virus through a
cell population is a complex process. To better understand how
viruses interact with the IFN response we have been following the
development of PIV5 plaques in cells that can produce and respond to
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slowly spread from cell-to-cell despite inducing limited amounts of
IFN. It achieves this by infecting cells in a pre-existing IFN-induced
anti-viral state and targeting STAT1 for degradation (Didcock et al.,
1999; Precious et al., 2007). In the absence of continuous IFN
signalling the cell cannot maintain its anti-viral state indeﬁnitely
and eventually normal virus replication is established (Carlos et al.,
2009; Precious et al., 2007). To further build up a picture of the factors
which govern how PIV5, and by extension other paramyxoviruses,
spread through cells which can produce and respond to IFN, we have
studied the dynamics of IFN production by cells within developing
PIV5 plaques. We present evidence that there is heterocellular
induction of the IFN-β promoter within PIV5 infected cells, thus
suggesting that only a few infected cells within developing plaques
are responsible for IFN that is produced. Similarly, evidence is
presented that only a few infected cells within developing plaques
of other members of the paramyxovirus family, as well as with
inﬂuenza A virus (strain Udorn) and bunyamwera virus, produce IFN,
suggesting that heterocellular production of IFN is a general
consequence of infection with negative strand RNA viruses.
Results
The establishment of an anti-viral state at the site of a developing PIV5
infection
To follow the induction of an IFN-induced anti-viral state in cells
surrounding sites of infection, A549 cells were seeded onto coverslips
and infected with PIV5 at an moi of 0.001 pfu per cell (i.e. under these
conditions most of the cells would not be infected at early time
points). At various times post-infection (p.i.), the cells were ﬁxed, and
infected cells identiﬁed by immunoﬂuorescence using an antibody
directed against the nucleoprotein (NP) of PIV5. The cell population
was also co-stained for MxA, which is an anti-viral protein induced in
uninfected cells as a consequence of IFN binding to the type I IFN
receptor. Two days after infection we routinely saw groups of 10–30
cells expressing viral antigen, indicative of viral replication and
spread. Surprisingly, only some of these groups of cells were
surrounded by a layer of cells that were positive for MxA (Fig. 1).
Continued monitoring of the size of groups of infected cells showed
that by 4 days p.i. all the remaining uninfected cells within the
infected monolayers were positive for MxA, demonstrating thatAnti-NP Anti-
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Fig. 1. At two days p.i., the uninfected cells surrounding developing plaquesmay (plaque 1), o
were infected at an moi of 0.001 pfu/cell. At 48 h p.i. the cells were ﬁxed, stained w
immunoﬂuorescence microscope.enough IFN had been secreted into the media to induce an anti-viral
state in all the uninfected cells (data not shown). From these initial
observations we concluded that by two days p.i., although some
infected cells must have produced IFN, this was not the case for all
infected cells.
Generation and characterisation of an A549/pr(IFN-β). GFP reporter cell
line
The heterogeneity of the MxA induction seen in the above
experiment could result from either heterogeneity or temporal lags
in the production or response of IFN. To distinguish between these
possibilities we generated an A549 reporter cell line in which IFN
productionwasmonitored by placing the eGFP gene under the control
of the IFN-β promoter. To generate such a cell line, the ﬁrst 282 bp of
the IFN-β promoter were cloned into a bicistronic lentivirus vector,
generating a plasmid (pdl′pIFNβ′GFP) such that following activation
of the IFN-β promoter both eGFP and pac (which confers puromycin
resistance) are expressed. Following transduction of A549 cells with
the vector, cells were ﬁrst subjected to puromycin selection for 2 days
following stimulation with dsRNA for 8 h. Subsequently surviving
cells were transfected with dsRNA for 8 h and GFP-positive single cells
separated by FACS into individual wells of a 96-well microtitre plate
such that a colony appeared in approximately 10–20% of wells. The
resulting colonies were screened for their ability to express GFP in
response to infection with a stock of MuV that we knew to be an
extremely good inducer of IFN as it contained large amounts of
defective interfering particles (DIs) that are powerful activators of the
IFN-induction cascade (this stock will be referred to hereafter as MuV
[ori]). The best colony of responding cells (termed A549/pr(IFN-β).
GFP) in terms of numbers of positive cells and intensity of GFP
expressionwas then further characterised. Fig. 2A shows that by 4 h p.
i. approximately 35% of cells were positive for GFP expression, by 6 h
p.i. 80% were positive and by 8 h p.i. 90% of the cells were strongly
positive upon infection with MuV(ori). FACS analysis of the MuV(ori)
infected cells showed a discrete population of GFP-positive cells
rather than a gradient of GFP-positive cells, suggesting that the IFN-β
promoter is either ‘on’ or ‘off’ in infected cells. Next, A549/pr(IFN-β).
GFP cells that had been grown on coverslips in 24-well Linbro plates
were infected with differing multiplicities of MuV(ori). At 24 h p.i. the
number of cells expressing GFPwas visualised by ﬂuorescence and the
amount of IFN in the culturemedium estimated using a CPE-reductionMxA merge
r may not (plaque 2), be positive for MxA. Monolayers of A549 cells grown on coverslips
ith anti-NP and anti-MxA antibodies, and visualised using a Nikon Microphot-FXA
GFP
mock infected
10 pfu/cell 
2 pfu/cell 
0.4 pfu/cell
0.08 pfu/cell 
IU IFN
640
0
320
160
20
4hp.i.
6h p.i.
8 h p.i.
35%
89%
79%
mock infected
A B
MuV (ori) 
M
uV
 (o
ri) 
m
u
m
ps NP
G
FP
Mock infected
A549/pr(IFN-b).GFP
/BVDV.NPro /HCV.NS3 4Aparentalparental
MuV (ori) 
3%
C D
co
n
tro
l
Ap
hi
di
co
lin
tre
at
ed
 
Fig. 2. Characterisation of the A549/pr(IFN-β).GFP reporter cells. (A). Monolayers of A549 cells were either mock-infected or infected with 5 pfu per cell of a stock of MuV (ori)
known to be a good inducer of IFN; at 4, 6 and 8 h p.i. the cells were trypsinised to a single cell suspension and the percentage of GFP-positive cells estimated by FACS analysis.
(B). Conﬂuent monolayers of A549/pr(IFN-β).GFP cells were grown in 60 mm dishes that contained coverslips and infected at various multiplicities of infection of MuV(ori). At 12 h
p.i. the coverslips were ﬁxed and those cells expressing GFP visualised using a NikonMicrophot-FXA ﬂuorescencemicroscopy. In addition, the amount of IFN secreted into the culture
medium was determined (right hand column). (C). A549/pr(IFN-β).GFP, A549/pr(IFN-β).GFP/BVBV.Npro or A549/pr(IFN-β).GFP/HCV.NS34a cells were either mock-infected of
infected with MuV(ori) at 5 pfu/cell. At 12 h p.i. the cells were ﬁxed and immunostained with an anti-NP mAb. GFP-positive and virus-infected cells were visualised by ﬂuorescence
microscopy. (D). A549/pr(IFN-β).GFP were, or were not (control), treated with aphidicolin (1 μg/ml) for 16 h, infected with MuV (ori) at 5 pfu/cell in the presence or absence of
aphidicolin as appropriate, ﬁxed at 16 h p.i. and GFP-positive cells visualised by ﬂuorescence microscopy.
249S. Chen et al. / Virology 407 (2010) 247–255bio-assay (Fig. 2B), showing that the number of cells expressing GFP
correlated with the amount of IFN produced.
To ensure expression of GFP was being activated by the well-
characterised IFN-induction pathways, we also determined the effect
of knocking out key signalling molecules involved in the IFN-induction cascade. To this end we engineered the A549/pr(IFN-β).
GFP reporter cell line to either constitutively express the NS3/4a
protein of HCV, which proteolytically cleaves the adaptor molecule
CARDIF/MAVS/IPS1/VISA, or the Npro protein of BVDV, which targets
IRF-3 for proteasome-mediated degradation. As expected, expression
250 S. Chen et al. / Virology 407 (2010) 247–255of either HCV NS3/4a or BVDV-Npro prevented induction of GFP
expression following infection of the cells with MuV (Fig. 2C).
Having successfully isolated a cell line in which GFP expression
was under the control of the IFN-β promoter we performed a series ofM
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Fig. 3. Detection of GFP-positive cells following infection of A549/pr(IFN-β).GFP cells with a
(cl3), PIV2, PIV3, PIV5, FLUAV or BUNV at 2–5 pfu/cell. At 16 h p.i. the cells were ﬁxed and im
by ﬂuorescence microscopy. The presence of the nuclei in the merge images was visualised badditional experiments to further characterise the cell line. Given that
the cells have been engineered such that they have at least one
additional IFN-β promoter it is theoretically possible that there
is competition between the inserted promoter and the naturalP merge
panel of negative strand RNA viruses. A549/pr(IFN-β).GFP cells were infected with MuV
munostained with an anti-NPmAb. GFP-positive and virus-infected cells were visualised
y DAPI staining. Note that MuV (cl3/30) was originally plaque-puriﬁed fromMuV (ori).
251S. Chen et al. / Virology 407 (2010) 247–255promoter. If this were the case it would be expected that the amount
of IFN secreted by the reporter cells would be less than that secreted
by the parental cell line. However, both cell lines produced similar
amounts of IFN when infected (data not shown). To determine
whether GFP expression was transient following activation of the IFN-
β promoter live cell microscopy was used to follow the fate of
individual cells that became positive for GFP expression over a 48 h
period. These studies demonstrated that once a cell had become
positive for GFP expression it remained positive (data not shown).
Finally, it has previously been suggested that the induction of the
IFN-β promoter may be dependent upon the cell cycle (Zawatzky et al.,
1985). Whilst this seems unlikely from the observation that N80% of
A549/pr(IFN-β).GFP cells growing asynchronously were positive for
GFP following infection with MuV (ori), we tested this directly by
arresting cells at the G1-S boundary using aphidicolin prior to infection
with MuV(ori). No difference was observed between the number of
GFP-positive cells that had or had not been treated with aphidicolin
demonstrating that the cell cycle does not inﬂuence the activation of the
IFN-β promoter in these reporter cell lines (Fig. 2D).
The data above show that efﬁcient inducers of IFN-β (i.e. a MuV
preparation rich in DI particles, or synthetic PAMPs; data not shown)
cause a robust induction of GFP expression in the majority of A549/pr
(IFN-β).GFP cells, with responsive cells producing similar levels of2 
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Fig. 4. Detection of GFP-positive cells within developing plaques of PIV5. A549/pr(IFN-β).GF
the cells were ﬁxed and immunostained with an anti-NP, and GFP-positive cells and infect
mixture of plaques which did, or did not, contain GFP-positive cells. By 4 days p.i. GFP-pos
remained negative for GFP. The presence of the nuclei in the merge images was visualisedﬂuorescence. We next used the A549/pr(IFN-β).GFP cells to monitor
the activation of the IFN-β promoter in individual cells during
infection by viruses generated by passage at low m.o.i. Such
preparations would be typical working stocks, lacking or low in DI
particles, and are generally poor inducers of IFN-β (see for example
Poole et al., 2002). Strikingly, in contrast to the extensive induction
seen by the DI-rich preparation, MuV(ori) — see Fig. 2, a plaque-
puriﬁed preparation of MuV, termedMuV cl3/30 (Young et al., 2009),
showed high infectivity but only generated a few GFP-positive cells
(Fig. 3). Each of the GFP-positive cells showed a similar degree of
ﬂuorescence, as described above for the MuV(ori) infection.
To investigate whether our observations on MuV were typical for
other RNA viruses we tested the paramyxoviruses PIV2, PIV3 and
PIV5, and the other negative-stranded RNA viruses, inﬂuenza A virus
(FLUAV), and bunyamwera virus (BUNV). Each of these viruses gave
similar results to plaque-puriﬁed MuV, i.e. efﬁcient infection of cells,
but a heterocellular induction of GFP (Fig. 3). Heterocellular induction
of IFN-β might account for the heterogeneity of the MxA induction
seen during PIV5 infection (see Fig. 1). To examine this directly we
used the A549/pr(IFN-β).GFP cells to monitor the activation of the
IFN-β promoter in individual cells within a developing plaque. A549/
pr(IFN-β).GFP reporter cells were infected with PIV5 at an moi of
0.001 pfu/cell and the expression of GFP monitored various timesP merge
P cells grown on coverslips were infected at an moi of 0.001 pfu/cell. At 2 and 4 days p.i.
ed cells visualised by ﬂuorescence microscopy. Note that at two days p.i. there were a
itive cells could be detected in all plaques, although the majority of infected cells still
by DAPI staining.
252 S. Chen et al. / Virology 407 (2010) 247–255post-infection. These results showed that GFP was expressed in only a
minority of infected cells within the developing plaques. At 2 days p.i.
there was a mixture of plaques in which either no cells were positive
for GFP expression, or in which only one or two GFP-positive cells
could be detected. However, by 4 days p.i. some GFP-positive cells
could be detected in all plaques (Fig. 4). The absence of GFP-positive
cells within some 2 day-old plaques suggested that the IFN-β
promoter had not been activated, and consequently IFN would not
have been secreted, by any of the cells within these plaques. To
determine if this was the case, we set up a similar experiment, but also
stained the monolayers for MxA as a marker for IFN activity (Fig. 5).
Consistent with the data shown in Fig. 1, at two days p.i. there were
some plaques in which none of the surrounding cells were positive for
MxA, whilst around other plaques the uninfected cells were positive
for MxA. Strikingly, expression of MxA directly correlated with the
presence of a GFP-positive cell within the developing plaques. If no
GFP-positive cells were detected, then the surrounding uninfected
cells were negative for MxA, whilst if there were one or more GFP-GFP Anti-PIV5
GFP Anti-PIV5
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Fig. 5. At two days p.i. there are a mixture of PIV5 plaques in which the IFN-β promoter has
coverslips were mock-infected, or were infected at an moi of 0.001 pfu/cell. At 2 days p.i.
positive cells (green), MxA-positive cells (blue) and infected cells (red) were visualised by co
speciﬁcity of the antibody, mock-infected cells were (+IFN) or were not (−IFN) treated with
whether the uninfected cells surrounding the plaque were positive for MxA; if a plaque con
negative.positive cells within a plaque then the surrounding cells were MxA-
positive. [Note that the cells in the centre of plaque 2 in Fig. 5 are
negative for MxA, presumably because in these cells, the ﬁrst to be
infected, the virus had targeted STAT1 for degradation and thus the cells
could not respond to IFN once it was secreted by the GFP-positive cell.]
We also examined whether the same effects were seen during the
course of other RNA virus infections. Each of PIV2, PIV3, FLUAV and
BUNV produce larger plaques on cells that have been engineered to
either not produce or respond to IFN (Fig. 6A), and thus some cells
must be secreting IFN that is inducing an anti-viral state in the
surrounding uninfected cells, thereby slowing the spread of the
infection. When the production of IFN was monitored using the GFP
reporter in A549/pr(IFN-β).GFP cells we observed that as seen for
PIV5, the cells surrounding infected cells in plaques in which no GFP-
positive cells could be detected, were negative for MxA expression
(Fig. 6B), suggesting that no cells within these plaques had yet been
activated to produce IFN. In contrast, the uninfected cells surrounding
plaques containing at least one GFP-positive cell were positive forAnti-MxA
-IFN +IFN
Anti-MxA merge
, or has not, been activated in some infected cells. A549/pr(IFN-β). GFP cells grown on
the cells were ﬁxed and immunostained with anti-NP and anti-MxA antibodies. GFP-
nfocal microscopy. To show that MxA is induced by IFN, its cytoplasmic distribution, and
IFN for 20 h and immunostained as above. Note that expression of GFP correlated with
tained a GFP-positive cell the surrounding cells were positive for MxA, if not they were
PIV2 PIV3
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Fig. 6. Heterocellular induction of the IFN-β promoter in developing plaques of PIV2, PIV3, FLUAV and BUNV. (A) PIV2, PIV3, FLUAV and BUNV form larger plaques on A549/BVDV-
Npro cells (that cannot to produce IFN) compared to parental A549 cells (which can produce and respond to IFN). (B) At 2 days p.i. some, but not all, PIV2, PIV3, FLUAV and BUNV
plaques contain a few cells in which the IFN-β promoter has been activated. A549/pr(IFN-β).GFP cells grown on coverslips were infected at anmoi of 0.001 pfu/cell. At 2 days p.i. the
cells were ﬁxed and immunostained with anti-NP and anti-MxA antibodies. GFP-positive cells (green), MxA-positive cells (blue/purple) and infected cells (red) were visualised by
ﬂuorescence microscopy. The presence of the nuclei in themerge images was visualised by DAPI staining. Note that expression of GFP always correlated with whether the uninfected
cells surrounding the plaque were positive for MxA; if a plaque contained a GFP-positive cell the surrounding cells were positive for MxA, if not they were negative.
253S. Chen et al. / Virology 407 (2010) 247–255MxA (Fig. 6B). The fact that for all the viruses studied induction of
MxA correlated with the presence of at least one GFP-positive cell
within the developing plaque conﬁrmed our previous conclusions
that expression of GFPwas a reliablemarker to identify cells that were
likely to have produced IFN. It should be noted that whilst the IFN-β
promoter must be activated to induce GFP expression, the lack of GFP
expression in infected cells could also be a consequence of post-
transcriptional regulation brought about by viral antagonists such as
the NS1 protein of FLUAV interfering with the processing and export
of cellular mRNAs from the nucleus to the cytoplasm. Nevertheless,
these results strongly suggest that only a limited number of cells
infected with negative-sense RNA viruses produce the IFN that
establishes an anti-viral state in the uninfected cells surrounding
the developing plaque, thereby slowing the spread of the infection.
Discussion
We have previously shown that when PIV5 infects cells in an IFN-
induced anti-viral state there are very signiﬁcant changes to thepattern of virus protein synthesis and cytoplasmic bodies containing
the NP, P and L proteins (Carlos et al., 2005) and virus genomes
become evident (Carlos et al., 2009). This IFN-induced anti-viral state
is extremely effective at reducing virus replication. However, PIV5 is
not eliminated from these cells but rather is able to dismantle the
anti-viral state in the absence of continuing IFN signalling, by
targeting STAT1 for proteolytic degradation (Precious et al., 2007);
complete destruction of STAT1 is a prelude to a recommencing of
normal PIV5 replication with the eventual release of virus. Neverthe-
less, the potential of IFN to signiﬁcantly slow the spread of virus
presents a formidable obstacle, and thus PIV5 has evolved a potent
mechanism(s) to limit IFN production (Andrejeva et al., 2004; Childs
et al., 2009; He et al., 2002; Poole et al., 2002). These mechanisms are
not fully effective however, as demonstrated by the fact that PIV5 (like
other negative strand RNA viruses) produces larger plaques in ‘IFN-
compromised’ cells than in ‘IFN-competent’ cells — i.e. at some point
at least some virus-infected cells must have secreted IFN thereby
slowing the spread of infection (data presented here, and Young et al.,
2003).
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responses during an ongoing PIV5 infection we observed that at
2 days p.i., uninfected cells surrounding some developing plaques did
not expressMxA and thus could not have been in an IFN-induced anti-
viral state (unpublished observations, Fig. 1). From this we concluded
that it was unlikely that IFN was synthesised and secreted from all
infected cells as otherwise the uninfected cells surrounding all the
plaques should have been positive for MxA. To further study the
dynamics of virus:host cell interactions that lead to the activation of
the IFN system, we generated a cell line (A549/pr(IFN-β).GFP) in
which the expression of GFP was under the control of the IFN-β
promoter. Most (at least 90%), if not all, of the cells in this population
are able to respond rapidly to efﬁcient inducers of IFN, in a manner
that depends upon the canonical signalling pathways. Having
established that GFP expression was a reliable marker to identify
individual cells in which the IFN-β promoter has been activated we
subsequently used the A549/pr(IFN-β).GFP reporter cells to follow
the induction of GFP in individual cells infected at a high moi by PIV5,
and also PIV2, PIV3, BUNV and FLUAV. These results clearly
demonstrated that GFP was only induced in a small minority of
infected cells. We also investigated the induction of GFP in individual
cells within developing plaques of these viruses. At two days p.i. some
plaques were readily visualised which contained no GFP-positive
cells, suggesting that IFN had not been produced in any of the infected
cells within these plaques. This conclusion was supported by the
observation that none of the uninfected cells surrounding plaques in
which there were no GFP-positive cells were positive for MxA. In
contrast, other plaques could also be detected in which a few of the
infected cells were positive for GFP and, furthermore, the uninfected
cells surrounding these plaques were always positive for MxA. Taken
together, these results strongly suggest that only a few cells within
developing plaques of negative-sense RNA viruses produce the IFN
that is responsible for inducing the anti-viral state in the surrounding
uninfected cells that reduces the speed of virus spread and
consequently plaque development.
It has been previously reported that the IFN-β gene shows
heterocellular induction in response to either the synthetic dsRNA,
poly(I).poly(C), or Sendai virus (Apostolou and Thanos, 2008; Enoch
et al., 1986; Hu et al., 2007; Senger et al., 2000; Zawatzky et al., 1985).
In none of these cases has the molecular basis of the restriction of
induction been determined, but it has been generally assumed to be a
property of the host cell; for example, it has been suggested that only
cells at certain stages of the cell cycle may be responsive (Zawatzky
et al., 1985). More recently, it has been demonstrated that the
percentage of cells able to support induction can be lowered by
overexpressing IRF-2, an antagonist of IFN-β transcription (Senger
et al., 2000), or raised by overexpressing the IFN-β transcriptional
activators p65 and/or IRF-3 (Apostolou and Thanos, 2008), suggesting
that the restriction is a result of the limited availability of transcription
factors. However, in our experiments, given that GFP can be induced
in at least 90% of the A549/pr(IFN-β).GFP cells (even in cells which
have been blocked in their cell cycle), and that the reporter gene does
not compete with the endogenous IFN-β gene, it clearly indicates that
induction in these cells is not restricted by transcription factor
availability or signalling pathway activation. Therefore, the hetero-
cellular induction observed in the A549/pr(IFN-β).GFP cells must be
due to the property of the infecting virus, rather than the ability of the
cells to respond to virus infection. Whilst variability in the infecting
virus population was not considered as a possible cause of the
observed heterocellular induction of the IFN-β promoter in most of
the previous studies, it remains possible that different cell typesmight
show very different percentages of cells able to support IFN-β
induction, with some cell lines, including A549 cells, able to induce
IFN in nearly every cell in a population.
It is well-established that most, if not all, viruses encode
antagonists of the IFN system, especially antagonists that limit IFNinduction (reviewed by Haller et al., 2006; Randall and Goodbourn,
2008). Given that the heterocellular induction of GFP is clearly a
property of the infecting virus, a critical question to address is why
GFP, and thus IFN, induced in some cells but not others. One possible
explanation is that the cells that become GFP-positive represent those
cells in which the virus has failed to block the signal transduction
pathways activated by viral PAMPs produced during normal virus
replication, or has globally failed to inhibit cellular transcription and
or protein synthesis. An alternative possibility is that the positive cells
contain virus infections that have either overproduced PAMPs, or have
perhaps produced a corrupt PAMP, such as that associated with DI
particles, which the virus-encoded IFN antagonists cannot block.
Regardless of the explanation for heterocellular induction of the IFN-β
promoter, it is clear from the approach taken here that there is still
much to be learnt about the processes and dynamics by which viruses
activate the IFN response and some of these questions will only be
answered by examining the activation of the IFN-β promoter in
individual cells. The A549/pr(IFN-β).GFP reporter cells, their deriva-
tives and/or equivalents, should prove to be invaluable tools in such
studies.Materials and methods
Cells, viruses and plasmids
Vero, MDCK and A549 cells, and their derivatives, were grown as
monolayers in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% (growth medium) or 2% (maintenance) foetal
bovine serum at 37 °C. PIV5 (strain W3A; Choppin, 1964), PIV2, PIV3,
MuV (strain Enders) and BUNV were grown and titrated under
appropriate conditions in Vero cells, or where stated on A549 cells.
FLUAV (strain Udorn)was grown and titrated onMDCK cells, or where
stated on A549 cells, in the presence of 2 μg/ml N-acteyl trypsin. The
construction and properties of cell lines expressing BVDV-Npro have
been previously described (Hilton et al., 2006) and hepatitis C virus
(HCV) NS3/4a-expressing cells were generated in a similar manner.
Brieﬂy, the NS3/4a gene was cloned into a modiﬁed self-inactivating,
bicistronic, lentiviral expression vector derived from pHR-SIN-CSGW
(Demaison et al., 2002), and used to generate recombinant lentivirus
particles thatwere used to select for cells that express V5-tagged NS3/
4a as previously described (Hilton et al., 2006).Immunoﬂuorescence, FACS and immunoblot analysis
The procedures for immunoblotting and immunoﬂuorescence
have previously been described (Carlos et al., 2005; Randall and
Dinwoodie, 1986). Antibodies used in these procedures included
monoclonal antibodies (mAbs) to the nucleoproteins of PIV2 (PIV2-
NPa, Randall and Young, 1988), PIV3 (4481, 4721 and 4812, a kind gift
from Claes Orvell, Karolinska Universitetssjukhuset, Sweden, Rydbeck
et al., 1986), PIV5 (PIV5-NPa, Randall et al., 1987), FLUAV (abcam,
ab20343) and a mAb to MxA (a kind gift from Otto Haller, University
of Freiburg, Germany, Flohr et al., 1999). Also used was a polyclonal
antibody to the NP of BUNV (a kind gift from Richard Elliott,
University of St Andrews). Following immunostaining, monolayers
were washed with PBS, mounted using either Citiﬂuor AF-1 mounting
solution (Citiﬂuor Ltd., UK) or Mowiol and examined with either a
Nikon Microphot-FXA immunoﬂuorescence microscope or a Zeiss
LSM 5 Exciter confocal microscope. For FACS analysis, cells were
trypsinised to a single cell suspension, ﬁxed and permeabilised as for
immunoﬂuorescence, and immunostained with the mAbs to the NP of
MuV. The percentage of ﬂuorescent cells, and intensity of their
ﬂuorescence in 10,000 events was determined by using the LYSYS
programme on a Becton Dickinson FACScan.
255S. Chen et al. / Virology 407 (2010) 247–255Interferon and interferon assays
Cells were treated with IFN-α (Roferon A, Roche) at 1000 U/ml.
The amount of IFN secreted by cells was determined by a CPE-
reduction bio-assay. Brieﬂy, culture supernatants from infected cells
were harvested, centrifuged at 1500×g for 10 min to pellet cellular
debris, UV-treated to inactivate residual virus, then serially diluted 2-
fold and added to A549/BVDV-Npro cell monolayers for 18 h prior to
infection with EMCV (0.05 pfu/cell). Monolayers were ﬁxed 2–3 days
post-infection (with PBS+5% formaldehyde) and cytopathic effect
(CPE) monitored by staining with 0.1% crystal violet.
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